Who we are

BioCurate is a bold, collaborative venture, dedicated to translating Australian medical research and delivering health and economic benefits to the world. Created jointly by two of Australia’s leading biomedical universities, the University of Melbourne and Monash University, we are operationally independent with an absolute commitment to rigorous science and partnering closely with researchers to help conquer the challenges which stand between great ideas and global impact. We can help you change the future.

We bridge the gap

Our collaborative team of global biomedical experts bridge the gap between:

Ideas + Impact
Research + Translation
Discovery + Commercialisation
Academia + Industry

What we are doing

This is the excerpt text that briefly describes what the page is about.
BioCurate is operationally independent of the Universities and has an independent Board Chair, the Hon John Brumby, AO. Mr Brumby is an eminent Australian with demonstrated leadership and commitment to innovation. He is supported by a highly experienced Board of Directors with specialist backgrounds in biotechnology and/or drug development commercialisation, investment and corporate governance.

Staff profiles

Our team

Has over 150 years of combined biotech/pharma industry experience

Has been directly involved in over 35 Investigational New Drug applications (INDs)

Are responsible for 70 therapeutics currently in the clinic

Were directly involved in 15 deals worth a cumulative total of over $2.1 billion

Twitter feed

Thank you #AusBio2023!

BioCurate had a wonderful time in Brisbane last week, reconnecting with peers, engaging in important discussions about the current state and future ambitions of Australia's biotech industry, and helping the development of the next generation of innovators.

Thank you Hit ID Symposium 2023!It was exciting to see fantastic talks covering a range of topics in drug development, starting at hit ID all the way through to the clinic and the market, being delivered to a deeply engaged and invested audience.

Abstract deadline extended until Monday 6th Nov to participate in the #I2T2023 pitch session.


Don't miss out!
⭐ Feedback from commercialization experts.
💲Total prize money of $30k for best speakers.
🗓 Tue, 5th Dec 23
📍 Woodward Conference Centre

Resuming after a short lunch break with a panel session on funding sources. Susie Nilsson from @CSIRO chairing the session wit MedChem Australia, Oncology One, @TIA_Aust ,@BioCurate and @brandoncapital’s Cureator.